FINWIRES · TerminalLIVE
FINWIRES

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

By

Axsome Therapeutics (AXSM) has an average rating of buy and mean price target of $280.53, according to analysts polled by FactSet.

What else is happening in Research?